NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis $6.60 -0.25 (-3.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.60 0.00 (0.00%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Mersana Therapeutics Stock (NASDAQ:MRSN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mersana Therapeutics alerts:Sign Up Key Stats Today's Range$6.37▼$6.8050-Day Range$6.60▼$10.1852-Week Range$6.37▼$70.75Volume110,562 shsAverage Volume130,548 shsMarket Capitalization$32.93 millionP/E RatioN/ADividend YieldN/APrice Target$130.00Consensus RatingModerate Buy Company Overview Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Read More Mersana Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreMRSN MarketRank™: Mersana Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 174th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Mersana Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Mersana Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted158.72% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 31.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.69 Percentage of Shares Shorted158.72% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 31.01%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $130.00 Consensus Price Target from BrokeragesAugust 2 at 2:06 AM | americanbankingnews.comMersana Therapeutics trading halted, news pendingJuly 26, 2025 | msn.comMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds).August 2 at 2:00 AM | American Alternative (Ad)Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025July 25, 2025 | msn.comMersana Therapeutics Announces 1-for-25 Reverse Stock SplitJuly 24, 2025 | globenewswire.comHead-To-Head Comparison: Mersana Therapeutics (NASDAQ:MRSN) vs. Lantern Pharma (NASDAQ:LTRN)July 24, 2025 | americanbankingnews.comMersana Therapeutics Settles Debt with Oxford FinanceJuly 3, 2025 | tipranks.comMersana Therapeutics Inc (MRSN) - Investing.comJuly 2, 2025 | investing.comSee More Headlines MRSN Stock Analysis - Frequently Asked Questions How have MRSN shares performed this year? Mersana Therapeutics' stock was trading at $35.75 on January 1st, 2025. Since then, MRSN stock has decreased by 81.5% and is now trading at $6.60. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its earnings results on Thursday, May, 15th. The company reported ($4.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.25) by $0.50. The business had revenue of $2.75 million for the quarter, compared to analysts' expectations of $6.05 million. Mersana Therapeutics had a negative net margin of 217.63% and a negative trailing twelve-month return on equity of 990.16%. Read the conference call transcript. When did Mersana Therapeutics' stock split? Mersana Therapeutics's stock reverse split on the morning of Friday, July 25th 2025.The 1-25 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings5/15/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRSN CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for Mersana Therapeutics$130.00 High Price Target$250.00 Low Price Target$75.00 Potential Upside/Downside+1,869.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($14.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.19 million Net Margins-217.63% Pretax Margin-216.41% Return on Equity-990.16% Return on Assets-48.87% Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.83 Sales & Book Value Annual Sales$40.50 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-3.44Miscellaneous Outstanding Shares4,990,000Free Float4,337,000Market Cap$32.93 million OptionableOptionable Beta0.83 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MRSN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.